Patents by Inventor Yung-Bin Kuo

Yung-Bin Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF UTILIZING ENZYME FOR ISOTHERMAL NUCLEIC ACID HYBRIDIZATION
    Publication number: 20190112646
    Abstract: The invention provides a method utilizing an enzyme to proceed isothermal nucleic acid hybridization. The invention uses the biological property of enzyme to replace the conventional heating process for denature or separating double-stranded nucleic acid. By practicing this invention, can a to-be-analyzed double-stranded nucleic acid, a correspondent specific nucleic acid probe and the enzyme be mixed together, and the nucleic acid hybridization can be achieved under constant temperature condition without multiple steps; furthermore, multiple targets hybridization reaction can be performed simultaneously.
    Type: Application
    Filed: January 12, 2018
    Publication date: April 18, 2019
    Inventors: ERR-CHENG CHAN, YUNG-BIN KUO
  • Method of PLSCR inhibition for cancer therapy
    Patent number: 8691229
    Abstract: The present invention relates to a method of using inhibitors of phospholipid scramblases (PLSCRs) for the prophylactic or therapeutic treatment of cancers. The PLSCR-inhibitors of the invention comprise compounds PLSCR-specific monoclonal antibodies, antagonists or nucleic acids, which have ability to decrease the level and/or biological activity of PLSCRs in cancer cells.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 8, 2014
    Assignee: Err-Cheng CHAN
    Inventors: Err-Cheng Chan, Hong-Arh Fan, Kuei-Tien Chen, Yung-Bin Kuo, Jinn-Shiun Chen, Chung-Wei Fan
  • METHOD OF PLSCR INHIBITION FOR CANCER THERAPY
    Publication number: 20130280242
    Abstract: The present invention relates to a method of using inhibitors of phospholipid scramblases (PLSCRs) for the prophylactic or therapeutic treatment of cancers. The PLSCR-inhibitors of the invention comprise compounds PLSCR-specific monoclonal antibodies, antagonists or nucleic acids, which have ability to decrease the level and/or biological activity of PLSCRs in cancer cells.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 24, 2013
    Inventors: Err-Cheng CHAN, Hong-Arh FAN, Kuei-Tien Chen, Yung-Bin Kuo, Jinn Shiun Chen, Chung-Wei Fan